Eli Lilly (LLY)

1,179.11
+0.00 (0.00%)
NYSE· Last Trade: Jul 20th, 6:24 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,179.11
Open-
Bid1,180.21
Ask1,184.55
Day's RangeN/A - N/A
52 Week Range623.78 - 1,249.45
Volume1,297
Market Cap1.13T
PE Ratio (TTM)51.38
EPS (TTM)22.9
Dividend & Yield6.920 (0.59%)
1 Month Average Volume3,050,063

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?fool.com
It is definitely a strong contender.
Via The Motley Fool · July 20, 2026
Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Yearsfool.com
Maybe you should, too.
Via The Motley Fool · July 19, 2026
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?fool.com
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
Via The Motley Fool · July 19, 2026
Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setupchartmill.com
Via Chartmill · July 17, 2026
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?fool.com
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?
Via The Motley Fool · July 18, 2026
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1fool.com
Viking's latest program seeks to push the envelope in weight loss efficacy.
Via The Motley Fool · July 18, 2026
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?fool.com
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
Via The Motley Fool · July 18, 2026
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Lossfool.com
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Via The Motley Fool · July 17, 2026
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Winfool.com
Novo Nordisk is finally getting one up on its biggest rival.
Via The Motley Fool · July 17, 2026
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternativesbenzinga.com
Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.
Via Benzinga · July 17, 2026
Why AtaiBeckley Stock Soared Todayfool.com
The psychedelic drugmaker is being acquired.
Via The Motley Fool · July 16, 2026
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billionfool.com
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
Via The Motley Fool · July 16, 2026
This GLP-1 Stock Could Double by 2030. Here's Whyfool.com
Investors need to ask tough questions before initiating a position in this biotech company.
Via The Motley Fool · July 16, 2026
Why Is GH Research Stock Trading Higher on Thursday?benzinga.com
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
Via Benzinga · July 16, 2026
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Dealbenzinga.com
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
Via Benzinga · July 16, 2026
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?fool.com
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Via The Motley Fool · July 16, 2026
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETFfool.com
IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.
Via The Motley Fool · July 16, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · July 16, 2026
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?fool.com
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.
Via The Motley Fool · July 16, 2026
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeoverinvestors.com
Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.
Via Investor's Business Daily · July 16, 2026
Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’benzinga.com
Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.
Via Benzinga · July 16, 2026
The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo?investors.com
FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.
Via Investor's Business Daily · July 16, 2026
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED)benzinga.com
AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
Via Benzinga · July 16, 2026
As Medicare’s New GLP-1 Coverage Begins, Ozari Health Publishes 2026 Guide Comparing Every Way to Get Semaglutide and Tirzepatide – From $50 Copays to $86 Cash-Pay Options
New York, NY - July 15, 2026 - The GLP-1 access landscape is changing faster in 2026 than at any point since these medications reached the market. Medicare's bridge payment demonstration — offering eligible beneficiaries GLP-1 medications at $50 monthly copays — begins this month. Branded Ozempic, Wegovy, Mounjaro, and Zepbound are now priced at $245 per month through federal pricing agreements announced in late 2025. Oral GLP-1options, including the Wegovy pill and newly approved orforglipron, have expanded the market beyond injections entirely.
Via AB Newswire · July 15, 2026
If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Todaybenzinga.com
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of $1.02 trillion.
Via Benzinga · July 15, 2026